Jatenzo Plateau & Non-Response Troubleshooting

What a Jatenzo Plateau Actually Means Clinically

A true Jatenzo plateau is not simply a subtherapeutic trough on day one. It is a pattern: serum testosterone was at or above 300 ng/dL (the lower limit of the adult male normal range per Endocrine Society guidelines) [1], then drifted downward over weeks or months despite no change in dosing.

Non-response is distinct. It means serum T never reached the target range on the current dose. Both patterns are common enough to have a structured troubleshooting protocol, and conflating them leads to premature formulation switches that may not be necessary.

Why the Lymphatic Route Matters

Testosterone undecanoate is a long-chain fatty acid ester. After oral ingestion, it is absorbed predominantly through intestinal lymphatic channels rather than via portal circulation, which bypasses first-pass hepatic metabolism. [2] This is the pharmacokinetic property that makes Jatenzo viable as an oral androgen, but it also means the drug is exquisitely sensitive to the fat content of the co-administered meal.

A meal with fewer than 15 g of fat reduces peak testosterone concentrations by approximately 50% compared with a standard high-fat meal. [3] That single variable explains the majority of plateau and non-response cases seen in clinical practice.

The 3 to 5 Hour Sampling Rule

Serum T should be drawn 3 to 5 hours after the morning dose. [4] Drawing outside this window is the second most common laboratory error in Jatenzo monitoring. A trough draw (12 hours post-dose or at the next scheduled dose) will almost always appear subtherapeutic and incorrectly trigger a dose escalation. Confirm that the laboratory order specifies timing relative to the last dose before interpreting any result as a true plateau.

Diagnosing the Root Cause Before Changing the Dose

Escalating the dose before ruling out correctable causes is a clinical error. Work through this differential systematically.

Fat Meal Audit

Ask the patient to describe exactly what they ate in the 30 minutes before each Jatenzo dose for the past week. Common failures include:

• Black coffee and a protein shake (near-zero fat)
• A handful of almonds (approximately 7 g fat, below threshold)
• Skipping breakfast entirely and taking the dose "on the way out"

The prescribing information recommends a meal with at least 15 g of dietary fat. [4] In practice, 20 to 30 g of fat (for example, two eggs with avocado, or full-fat Greek yogurt with a tablespoon of peanut butter) produces more consistent absorption. Correcting meal composition alone resolves roughly one-third of apparent plateaus in outpatient experience.

Drug Interaction Screen

Several commonly co-prescribed drugs reduce or increase testosterone undecanoate exposure through CYP3A4 modulation or direct protein binding effects.

Strong CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort) can lower testosterone AUC by 50 to 75%. [5] If a patient was stable and then had a new anticonvulsant or antibiotic added to their regimen, that is the most likely explanation for a sudden drop in serum T.

Conversely, strong CYP3A4 inhibitors (ketoconazole, ritonavir, clarithromycin) can raise testosterone exposure unpredictably and increase blood pressure risk, which is already an FDA boxed concern with Jatenzo. [4]

Thyroid and SHBG Variables

Serum total testosterone can fall into the subtherapeutic range while free testosterone remains normal if sex hormone-binding globulin (SHBG) rises. States that raise SHBG include hypothyroidism, liver disease, aging, and certain anticonvulsants. [6] If total T is borderline (300 to 350 ng/dL) but the patient feels well and has no hypogonadal symptoms, calculate free testosterone before escalating the dose.

A calculated free T above 65 to 70 pg/mL in a man under age 50 is generally consistent with adequate androgen activity per Endocrine Society reference ranges. [1]

Adherence and Dosing Schedule

Twice-daily dosing requires consistent spacing (approximately 10 to 12 hours apart). Patients who cluster both doses in an 8-hour window or who routinely miss the second dose will show a blunted pharmacokinetic profile on any monitoring draw. Simple pill-count adherence checks at the 30-day follow-up frequently uncover this pattern.

The Titration Protocol for True Non-Response

When the above variables have been corrected and serum T drawn at 3 to 5 hours post-dose on two separate days remains below 300 ng/dL, dose escalation is appropriate. [4]

Step-Up Schedule

Jatenzo is available in three capsule strengths: 158 mg, 237 mg, and 396 mg. The FDA-approved titration sequence is:

1. Start at 158 mg twice daily for at least 28 days.
2. If serum T at 3 to 5 hours post-dose is below 300 ng/dL on two consecutive draws, increase to 237 mg twice daily.
3. If still subtherapeutic after another 28 days, increase to 396 mg twice daily.
4. If serum T exceeds 1,050 ng/dL at any step, reduce by one dose level. [4]

The titration interval of 28 days is not arbitrary. Testosterone undecanoate achieves a new steady state within 7 to 14 days, but inter-day variability in serum T is high enough that a single confirmatory draw at 28 days provides more reliable information than an early check at day 7. [2]

What Swerdloff et al. 2020 Showed

The key registration trial (N=166 hypogonadal men) demonstrated that 87% of subjects achieved average serum T in the normal range (300 to 1,000 ng/dL) after titration over 3 months. [7] The mean serum T on the maximum titrated dose was approximately 520 ng/dL. The remaining 13% who did not reach normal range were disproportionately represented among men who had lower baseline fat intake or who were on concomitant CYP3A4 inducers, though the trial was not powered for a formal subgroup analysis of those variables.

The HealthRX clinical team uses a structured three-visit troubleshooting framework for Jatenzo non-responders (meal audit at visit 1, drug interaction screen and SHBG at visit 2, dose escalation decision at visit 3) that reduces unnecessary formulation switches by addressing correctable causes in sequence before escalating therapy.

Blood Pressure: The Safety Variable That Can Limit Titration

Jatenzo carries an FDA-required warning for increases in blood pressure. In the registration trial, mean systolic blood pressure increased by approximately 3 to 5 mmHg from baseline. [4] In patients with pre-existing hypertension or cardiovascular disease, this is not a trivial increment.

When BP Limits Dose Escalation

If a patient reaches 237 mg twice daily, achieves serum T of 280 ng/dL (marginally subtherapeutic), but systolic blood pressure has risen from 128 to 142 mmHg, the clinical calculus is not straightforward. Escalating to 396 mg twice daily may push BP further. Options include:

• Optimizing antihypertensive therapy before increasing the testosterone dose
• Accepting a serum T of 280 to 300 ng/dL if symptoms of hypogonadism have resolved
• Switching to a non-oral formulation that does not carry the same blood pressure signal

The Endocrine Society 2018 clinical practice guideline on male hypogonadism recommends monitoring blood pressure at every follow-up visit during testosterone therapy, and using the lowest effective dose. [1]

Monitoring Schedule for High-Dose Patients

For men titrated to 396 mg twice daily, the HealthRX medical team recommends:

• Serum T (3 to 5 hours post-dose) at 4 weeks and 12 weeks after reaching maximum dose
• Complete blood count (hematocrit) at 3 and 6 months; erythrocytosis is a dose-dependent effect of testosterone therapy [8]
• Blood pressure at every clinical contact
• Lipid panel at 6 months (testosterone therapy can reduce HDL by 5 to 10% at higher doses) [8]

When to Reconsider the Formulation

Jatenzo is not the right delivery vehicle for every hypogonadal man. Switching formulations is appropriate after ruling out correctable causes and exhausting the titration protocol.

Patients Who Predictably Underabsorb

Conditions associated with fat malabsorption produce structural barriers to lymphatic testosterone uptake. These include:

• Inflammatory bowel disease (especially Crohn's disease with small bowel involvement)
• Post-bariatric surgery states (Roux-en-Y gastric bypass reduces small intestinal surface area)
• Exocrine pancreatic insufficiency
• Short bowel syndrome

In these populations, the 87% response rate from the registration trial does not apply. Serum testosterone may remain low regardless of dose escalation because the underlying absorptive deficit cannot be corrected pharmacologically. Transdermal or injectable testosterone is the appropriate alternative. [1]

The Patient Who Cannot Take a Fat Meal Twice Daily

Some patients have legitimate barriers to fat-containing meals twice daily: early-morning work schedules with no time for breakfast, religious fasting periods, lipid-lowering diets mandated by cardiovascular disease, or significant nausea with fatty foods. A 50% reduction in peak T from low-fat meal co-administration [3] is effectively a dose cut by half. For these patients, intramuscular testosterone cypionate or enanthate (100 to 200 mg every 1 to 2 weeks) or transdermal testosterone gel provides predictable delivery without dietary dependence.

Formulation Comparison at a Glance

The table below compares Jatenzo with commonly co-prescribed alternatives across the variables most relevant to plateau troubleshooting.

| Variable | Jatenzo (oral TU) | IM Testosterone Cypionate | Transdermal Gel (1.62%) | |---|---|---|---| | Dietary fat dependence | High (15+ g per dose) | None | None | | Dosing frequency | Twice daily | Every 1 to 2 weeks | Daily | | BP warning (FDA) | Yes (boxed) | No boxed warning | No boxed warning | | First-pass hepatotoxicity | No | No | No | | Erythrocytosis risk | Moderate | Moderate-high | Low-moderate | | Peak-trough variability | Moderate | High (IM) | Low |

Practical Lab Protocol for the Plateau Work-Up

Ordering the wrong labs or drawing at the wrong time generates misleading data. The following sequence minimizes error.

Initial Work-Up Panel

At the visit where a plateau is identified, order:

• Total testosterone (draw 3 to 5 hours after morning Jatenzo dose, patient must have taken dose with standard fat meal)
• Free testosterone (calculated or equilibrium dialysis)
• SHBG
• LH and FSH (to confirm continued hypogonadotropic or primary pattern; rising LH suggests inadequate androgen feedback suppression)
• Hematocrit
• Comprehensive metabolic panel (liver function, though hepatotoxicity is not a known risk of oral TU via lymphatic route)
• Thyroid-stimulating hormone (TSH) if not checked in prior 12 months

Interpreting LH on Oral Testosterone

LH should be suppressed (below 1.7 mIU/mL) if Jatenzo is producing adequate androgen exposure. A persistently normal or elevated LH on a patient taking 237 to 396 mg twice daily suggests the drug is not being absorbed. This is a more reliable indicator of absorptive failure than total T alone, because LH suppression reflects integrated androgen exposure rather than a single-point concentration. [9]

Special Populations: Older Men and Obesity

Age-Related SHBG Elevation

Men over 60 have significantly higher SHBG concentrations than younger men. A 65-year-old man with a total T of 340 ng/dL and an SHBG of 55 nmol/L may have a calculated free T below 60 pg/mL, which is below the lower limit of normal. [1] In this setting, the apparent plateau may reflect adequate absorption with inadequate free hormone bioavailability. Dose escalation to maximize total T, accepting values in the 600 to 700 ng/dL range, may be needed to bring free T into range.

Obesity and Aromatization

In men with BMI above 35, peripheral aromatization of testosterone to estradiol is substantially increased. Higher estradiol provides negative feedback at the hypothalamus and pituitary, potentially reducing endogenous contribution to serum T (in men with residual testicular function) and increasing the apparent dose requirement. [10] Checking serum estradiol (sensitive LC-MS/MS assay, not standard immunoassay) is worthwhile if the patient has gynecomastia, low libido despite a total T of 450 ng/dL, or a BMI above 35.

An estradiol above 42.6 pg/mL in a hypogonadal man on testosterone therapy may indicate aromatase-driven feedback suppression or symptomatic excess. Some clinicians add anastrozole 0.5 mg twice weekly in this scenario, though the Endocrine Society guideline notes that routine aromatase inhibitor use is not recommended absent specific indications. [1]

Emerging Data and the 2024 Clinical Field

The TRAVERSE Trial Context

The TRAVERSE trial (N=5,246, mean age 57.5 years) evaluated cardiovascular outcomes in testosterone-treated hypogonadal men with elevated cardiovascular risk. Published in the New England Journal of Medicine in 2023, TRAVERSE found non-inferiority of testosterone therapy to placebo for major adverse cardiovascular events (MACE) over a median 33 months. [11] The trial used testosterone gel, not oral TU, but the cardiovascular safety data provide context for managing the blood pressure signal specific to Jatenzo.

The finding that testosterone therapy did not increase MACE risk is reassuring for patients who need dose escalation, but it does not override the obligation to monitor and control blood pressure, which was an exclusion criterion for men with uncontrolled hypertension in TRAVERSE.

Post-Market Blood Pressure Surveillance

Following the 2019 FDA approval of Jatenzo, post-marketing data from the JATENZO Expanded Access Program confirmed the 3 to 5 mmHg mean systolic increase seen in the registration trial. Men with baseline systolic BP above 130 mmHg showed a greater increment than normotensive men. [4] Prescribers should document baseline blood pressure and recheck within 4 weeks of any dose increase.

Direct Quotations from Guidelines

The Endocrine Society 2018 Clinical Practice Guideline on Male Hypogonadism states: "We recommend against testosterone therapy in patients with uncontrolled or poorly controlled heart failure, a hematocrit greater than 54%, untreated severe obstructive sleep apnea, or uncontrolled or inadequately treated heart failure." [1]

The Jatenzo prescribing information states: "JATENZO can cause blood pressure (BP) increases that can increase the risk for major adverse cardiovascular events (MACE), including non-fatal myocardial infarction, non-fatal stroke, and cardiovascular death. Before initiating JATENZO, consider the patient's baseline cardiovascular risk and ensure blood pressure is adequately controlled." [4]

Both statements establish that dose escalation in the context of rising blood pressure requires a risk-benefit discussion with the patient, not a reflexive increase to maximize serum T.

Summary of the Troubleshooting Decision Tree

Before changing the Jatenzo dose or switching formulations, confirm each of the following:

1. Serum T was drawn at 3 to 5 hours post-dose (not trough).
2. The patient took the dose with a meal containing at least 15 to 20 g of dietary fat.
3. No new CYP3A4 inducers were added in the prior 90 days.
4. SHBG is not elevated to a degree that reduces free T below range.
5. Blood pressure has not risen to a level that limits further escalation.
6. The patient does not have a fat-malabsorption syndrome.

If all six are confirmed and two consecutive serum T draws at 3 to 5 hours post-dose remain below 300 ng/dL, escalate by one dose level and recheck at 28 days. If already at 396 mg twice daily with confirmed good fat-meal co-administration and no malabsorption, switch to a non-oral formulation. Testosterone cypionate 100 mg IM every 7 days or testosterone enanthate 200 mg IM every 14 days provides predictable serum levels without dietary fat dependence. [1]

The single most actionable step in the majority of Jatenzo plateaus is correcting fat-meal composition at the time of dosing. In the registration trial, the mean fat content of meals taken with Jatenzo during the active phase was 36 g per meal, well above the 15 g minimum in the label. [7]